Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID ‐19 pandemic in Italy

Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: Data from the DA‐COVID‐19 registry

(2021) Andrea Chiricozzi et al.   ALLERGY

Dupilumab and COVID ‐19: What should we expect?

(2020) Cataldo Patruno et al.   Dermatologic Therapy

Complete Skin Clearance and PASI response rates in clinical practice‐ Predictors, Health Related Quality of Life improvements and implications for treatment goals

(2019) J. M. Norlin et al.   BRITISH JOURNAL OF DERMATOLOGY

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase II a open‐label trial and subsequent phase III open‐label extension

(2019) M.J. Cork et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

(2019) Eric L. Simpson et al.   JAMA Dermatology

Suicidal Ideation, Mental Health Problems, and Social Function in Adolescents with Eczema: A Population-Based Study

(2014) Jon A. Halvorsen et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization

(2013) Jonathan I. Silverberg et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis

(2011) Marcia J. Slattery et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three

(2009) Joseph A. Odhiambo et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY